Loading…
Reported covered position: Senior Health Policy Advisor and Counsel Sen Cassidy; Advisor Rep. Cassidy; Healthcare Aide Sen. Enzi
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. · Firm: BGR GOVERNMENT AFFAIRS
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. · Firm: BGR GOVERNMENT AFFAIRS
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
GRADY HEALTH SYSTEM via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and policy advocacy related to federal payment and policy issues and government funding impacting hospitals generally and Grady Health System specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Postal Service (USPS)
VAXCYTE, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Source: Senate LDA
| SENIOR CARE PHARMACY COALITION |
| 39 |
| 2017–2026 |
| AMEDISYS, INC. | 38 | 2017–2026 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 36 | 2018–2026 |
| LOCKTON MANAGEMENT, LLC | 36 | 2017–2026 |
| WALGREEN CO | 36 | 2018–2026 |
| ABIOMED INC | 35 | 2017–2025 |
| EDWARDS LIFESCIENCES LLC | 35 | 2018–2026 |
| AMERICAN HEALTH CARE ASSOCIATION | 34 | 2018–2026 |
| KIDNEY CARE PARTNERS | 33 | 2018–2026 |
| U.S. ANESTHESIA PARTNERS, INC. | 33 | 2018–2026 |
| SCP-HEALTH | 32 | 2019–2026 |
| AKEBIA THERAPEUTICS, INC. | 30 | 2019–2026 |
| MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) | 29 | 2020–2026 |
| U.S. ACUTE CARE SOLUTIONS, LLC | 29 | 2019–2026 |
| BAYER CORPORATION | 27 | 2019–2025 |
| CENTENE CORPORATION | 27 | 2018–2026 |
| GLAXOSMITHKLINE, INC. | 27 | 2020–2026 |
| PTC THERAPEUTICS | 26 | 2020–2026 |
| EPIGENOMICS INC. | 24 | 2017–2022 |
| LUMEXA IMAGING, INC. (FKA US RADIOLOGY SPECIALISTS) | 23 | 2021–2026 |
| OAK STREET HEALTH D/B/A CVS HEALTH | 23 | 2021–2026 |
| RADIOLOGY PARTNERS | 23 | 2021–2026 |
| Zogenix, Inc. | 22 | 2017–2022 |
| ALLIANCE FOR REGENERATIVE MEDICINE | 21 | 2022–2026 |
| FINDHELP | 21 | 2021–2026 |
| HORIZON PHARMA | 21 | 2019–2023 |
| STRYKER CORPORATION | 21 | 2020–2025 |
| THE ASSISTANCE FUND | 18 | 2021–2024 |
| NOVARTIS | 17 | 2023–2026 |
| IMPOSSIBLE FOODS INC. | 15 | 2019–2022 |
| PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 15 | 2017–2020 |
| SIEMENS HEALTHINEERS | 15 | 2019–2023 |
| ACADEMY OF NUTRITION & DIETETICS | 14 | 2024–2026 |
| AMERICAN BEVERAGE ASSOCIATION | 14 | 2017–2020 |
| MERCK & CO., INC. | 13 | 2017–2020 |
| REAL TIME MEDICAL SYSTEMS | 13 | 2023–2026 |
| ShiftKey, LLC | 13 | 2023–2026 |
| ADVOCATE HEALTH | 12 | 2024–2026 |
| ALKERMES, INC. | 12 | 2017–2019 |
| Alnylam Pharmaceuticals, Inc. | 12 | 2017–2019 |
| BIOMARIN PHARMACEUTICAL INC. | 12 | 2023–2025 |
| CELGENE CORPORATION | 12 | 2017–2019 |
| FLEXION THERAPEUTICS, INC. | 12 | 2017–2019 |
| SELECT MEDICAL CORPORATION | 12 | 2022–2025 |
| ADVANCED MEDICAL TECHNOLOGY ASSOCIATION | 11 | 2017–2019 |
| ELI LILLY & CO INC | 11 | 2017–2019 |
| GRADY HEALTH SYSTEM | 11 | 2024–2026 |
| NYU LANGONE HEALTH | 11 | 2024–2026 |
| ASSOCIATION FOR RESPONSIBLE HEALTHCARE INVESTMENT | 10 | 2025–2026 |
| UROGEN PHARMA, INC. | 10 | 2022–2024 |
| NEKTAR THERAPEUTICS | 9 | 2020–2022 |
| INDUCTIVEHEALTH INFORMATICS | 8 | 2025–2026 |
| NATIONAL ALLIANCE FOR CARE AT HOME | 8 | 2025–2026 |
| PHYSICIANS FOR FAIR COVERAGE | 8 | 2018–2020 |
| SANOFI US SERVICES INC | 8 | 2017–2018 |
| THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 8 | 2025–2026 |
| BAUDAX BIO, INC. (FORMERLY KNOWN AS RECRO PHARMA, INC.) | 7 | 2019–2020 |
| COLORECTAL CANCER ALLIANCE | 6 | 2025–2026 |
| GILEAD SCIENCES, INC. | 6 | 2017–2018 |
| Karyopharm Therapeutics Inc. | 6 | 2018–2019 |
| SAS INSTITUTE, INC. | 6 | 2022–2023 |
| Vaxcyte, Inc. | 6 | 2025–2026 |
| AMARIN PHARM INC. | 5 | 2019–2020 |
| BLUEBIRD BIO | 5 | 2019–2020 |
| DISPOSERX, INC. | 5 | 2019–2020 |
| EISAI INC. | 5 | 2017 |
| GENENTECH INC | 5 | 2017–2018 |
| EIGER BIOPHARMACEUTICALS, INC. | 4 | 2020–2021 |
| FEDERATION OF AMERICAN HOSPITALS | 4 | 2026 |
| MATRIX MEDICAL NETWORK | 4 | 2020–2021 |
| MLK COMMUNITY HEALTHCARE | 4 | 2021 |
| PROLACTA BIOSCIENCE, INC. | 4 | 2024–2025 |
| AMBULNZ | 3 | 2020 |
| CARLSMED, INC. | 3 | 2024 |
| CURANA HEALTH, INC. | 3 | 2026 |
| PHI HEALTH, LLC, D/B/A PHI AIR MEDICAL | 3 | 2026 |
| PREMIA SPINE | 3 | 2026 |
| ROIVANT SCIENCES, INC. | 3 | 2017 |
| TEAMHEALTH | 3 | 2026 |
| VITAE HEALTH SYSTEMS | 3 | 2026 |
| AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION | 2 | 2026 |
| AVANIR PHARMACEUTICALS, INC. | 2 | 2018 |
| CARDINAL HEALTH | 2 | 2018 |
| EGALET CORPORATION | 2 | 2017 |
| INTERSYSTEMS PUBLIC SECTOR CORPORATION | 2 | 2026 |
| NASSAU HEALTH SYSTEM CORP. | 2 | 2025 |
| NEPHROLOGY ASSOCIATES OF NORTHERN ILLINOIS AND INDIANA | 2 | 2021 |
| NJOY, LLC | 2 | 2019 |
| SOBI NORTH AMERICA | 2 | 2019 |
| SWORD HEALTH | 2 | 2025–2026 |
| ANHEUSER-BUSCH COMPANIES | 1 | 2018 |
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. · Firm: BGR GOVERNMENT AFFAIRS
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031/ S.3159 Preserving Patient Access to Long-Term Care Pharmacies Act
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031/ S.3159 Preserving Patient Access to Long-Term Care Pharmacies Act
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031/ S.3159 Preserving Patient Access to Long-Term Care Pharmacies Act
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031/ S.3159 Preserving Patient Access to Long-Term Care Pharmacies Act
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031/ S.3159 Preserving Patient Access to Long-Term Care Pharmacies Act
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031/ S.3159 Preserving Patient Access to Long-Term Care Pharmacies Act
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. · Firm: BGR GOVERNMENT AFFAIRS
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. · Firm: BGR GOVERNMENT AFFAIRS
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. · Firm: BGR GOVERNMENT AFFAIRS
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031/ S.3159 Preserving Patient Access to Long-Term Care Pharmacies Act
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031 Preserving Patient Access to Long-Term Care Pharmacies Act
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031/ S.3159 Preserving Patient Access to Long-Term Care Pharmacies Act
Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act
Client: SELECT MEDICAL CORPORATION · Firm: BGR GOVERNMENT AFFAIRS
Medicare prospective payment system; Long Term Acute Care Hospitals (LTCH); implementation of health care reform; Physician fee schedule and IMPACT Act; Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act (S. 2834 / HR 5503); High Cost Outlier program
Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act
Client: SELECT MEDICAL CORPORATION · Firm: BGR GOVERNMENT AFFAIRS
Medicare prospective payment system; Long Term Acute Care Hospitals (LTCH); implementation of health care reform; Physician fee schedule and IMPACT Act; Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act (S. 2834 / HR 5503); High Cost Outlier program
Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act
Client: SELECT MEDICAL CORPORATION · Firm: BGR GOVERNMENT AFFAIRS
Medicare prospective payment system; Long Term Acute Care Hospitals (LTCH); implementation of health care reform; Physician fee schedule and IMPACT Act; Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act (S. 2834 / HR 5503); High Cost Outlier program
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act of 2022
Client: SELECT MEDICAL CORPORATION · Firm: BGR GOVERNMENT AFFAIRS
Medicare prospective payment system; Long Term Acute Care Hospitals (LTCH); implementation of health care reform; Physician fee schedule and IMPACT Act; Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act (S. 2834 / HR 5503); High Cost Outlier program
Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act of 2022
Client: SELECT MEDICAL CORPORATION · Firm: BGR GOVERNMENT AFFAIRS
Medicare prospective payment system; Long Term Acute Care Hospitals (LTCH); implementation of health care reform; Physician fee schedule and IMPACT Act; Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act (S. 2834 / HR 5503); High Cost Outlier program
Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act of 2022
Client: SELECT MEDICAL CORPORATION · Firm: BGR GOVERNMENT AFFAIRS
Medicare prospective payment system; Long Term Acute Care Hospitals (LTCH); implementation of health care reform; Physician fee schedule and IMPACT Act; Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act (S. 2834 / HR 5503); High Cost Outlier program
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, biopharma innovation policies and Rare Pediatric Disease Priority Review Voucher program policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, biopharma innovation policies and Rare Pediatric Disease Priority Review Voucher program policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act
Client: SELECT MEDICAL CORPORATION · Firm: BGR GOVERNMENT AFFAIRS
Medicare prospective payment system; Long Term Acute Care Hospitals (LTCH); implementation of health care reform; Physician fee schedule and IMPACT Act; Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act (S. 2834 / HR 5503); High Cost Outlier Program
Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act
Client: SELECT MEDICAL CORPORATION · Firm: BGR GOVERNMENT AFFAIRS
Medicare prospective payment system; Long Term Acute Care Hospitals (LTCH); implementation of health care reform; Physician fee schedule and IMPACT Act; Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act (S. 2834 / HR 5503); High Cost Outlier Program
Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act
Client: SELECT MEDICAL CORPORATION · Firm: BGR GOVERNMENT AFFAIRS
Medicare prospective payment system; Long Term Acute Care Hospitals (LTCH); implementation of health care reform; Physician fee schedule and IMPACT Act; Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act (S. 2834 / HR 5503); High Cost Outlier Program
Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act
Client: SELECT MEDICAL CORPORATION · Firm: BGR GOVERNMENT AFFAIRS
Medicare prospective payment system; Long Term Acute Care Hospitals (LTCH); implementation of health care reform; Physician fee schedule and IMPACT Act; Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act (S. 2834 / HR 5503); High Cost Outlier Program
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act of 2022
Client: SELECT MEDICAL CORPORATION · Firm: BGR GOVERNMENT AFFAIRS
Medicare prospective payment system; Long Term Acute Care Hospitals (LTCH); implementation of health care reform; Physician fee schedule and IMPACT Act; Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act (S. 2834 / HR 5503); High Cost Outlier Program
Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act of 2022
Client: SELECT MEDICAL CORPORATION · Firm: BGR GOVERNMENT AFFAIRS
Medicare prospective payment system; Long Term Acute Care Hospitals (LTCH); implementation of health care reform; Physician fee schedule and IMPACT Act; Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act (S. 2834 / HR 5503); High Cost Outlier Program
Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act of 2022
Client: SELECT MEDICAL CORPORATION · Firm: BGR GOVERNMENT AFFAIRS
Medicare prospective payment system; Long Term Acute Care Hospitals (LTCH); implementation of health care reform; Physician fee schedule and IMPACT Act; Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act (S. 2834 / HR 5503); High Cost Outlier Program
Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act of 2022
Client: SELECT MEDICAL CORPORATION · Firm: BGR GOVERNMENT AFFAIRS
Medicare prospective payment system; Long Term Acute Care Hospitals (LTCH); implementation of health care reform; Physician fee schedule and IMPACT Act; Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act (S. 2834 / HR 5503); High Cost Outlier Program
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act
Client: SELECT MEDICAL CORPORATION · Firm: BGR GOVERNMENT AFFAIRS
Medicare prospective payment system; Long Term Acute Care Hospitals (LTCH); implementation of health care reform; Physician fee schedule and IMPACT Act; Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act (S. 2834 / HR 5503)
Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act
Client: SELECT MEDICAL CORPORATION · Firm: BGR GOVERNMENT AFFAIRS
Medicare prospective payment system; Long Term Acute Care Hospitals (LTCH); implementation of health care reform; Physician fee schedule and IMPACT Act; Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act (S. 2834 / HR 5503)
Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act
Client: SELECT MEDICAL CORPORATION · Firm: BGR GOVERNMENT AFFAIRS
Medicare prospective payment system; Long Term Acute Care Hospitals (LTCH); implementation of health care reform; Physician fee schedule and IMPACT Act; Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act (S. 2834 / HR 5503)
Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act
Client: SELECT MEDICAL CORPORATION · Firm: BGR GOVERNMENT AFFAIRS
Medicare prospective payment system; Long Term Acute Care Hospitals (LTCH); implementation of health care reform; Physician fee schedule and IMPACT Act; Dr. Joanne Smith Memorial Rehabilitation Innovation Centers Act (S. 2834 / HR 5503)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Provide strategic counsel and advocate on issues related to vaccine development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NYU LANGONE HEALTH via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and NYU Langone Health specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ACADEMY OF NUTRITION AND DIETETICS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to health care coverage for Medical Nutritional Therapy and Intensive behavior health and other priorities for the Academy of Nutrition and Dietetics
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals and health plans generally and Mass General Brigham specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE
PTC THERAPEUTICS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and advocacy with regard to regulations and legislation that could impact the pharmaceutical industry generally, and PTC specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCP-HEALTH via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic guidance and counsel on policy issues impacting emergency medicine and issues related to acute unscheduled care including physician fee schedule
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AKEBIA THERAPEUTICS, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic guidance and counsel on issues impacting the biopharmaceutical industry and legislation to provide greater access to kidney care.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
U.S. ACUTE CARE SOLUTIONS, LLC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provided strategic counsel on matters before HHS and the Congress, including surprise medical billing and Medicare payment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN SOCIETY OF GENE AND CELL THERAPY via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Strategic advice and counsel on issues impacting gene and cell therapy development and access
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WALGREEN CO. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide policy analysis, strategic advice and direct advocacy support to Walgreens related to public policy priorities for the retail pharmacy industry
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, White House Office
EDWARDS LIFESCIENCES LLC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Advise and advocate on client's behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CENTENE CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Strategic guidance and counsel related to Medicare, Medicaid, and the insurance market.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ADVOCATE HEALTH via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on health care policy, including matters impacting the hospital industry and federal appropriations
Provide strategic counsel and advocate on health care policy, including matters impacting the hospital industry and federal appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NEUROCRINE BIOSCIENCES, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LOCKTON MANAGEMENT, LLC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Strategic guidance and counsel on maintaining and strengthening the employer-based health care system, and advise the client on legislative and regulatory issues.
Filing targets: Commodity Futures Trading Commission (CFTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Science & Technology Policy (OSTP), SENATE, Securities & Exchange Commission (SEC), Transportation, Dept of (DOT), Treasury, Dept of
U.S. ANESTHESIA PARTNERS, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provided strategic counsel on matters before HHS and the Congress, including surprise medical billing and Medicare payment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SENIOR CARE PHARMACY COALITION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031/ S.3159 Preserving Patient Access to Long-Term Care Pharmacies Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
SHIFTKEY, LLC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to healthcare workforce and technology and independent contractor classification
Filing targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE, Veterans Affairs, Dept of (VA)
AMERICAN HEALTH CARE ASSOCIATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Long-term care reform; Medicare and Medicaid payment policy; Medicare Advantage policy; arbitration issues; implementation of health care reform; bad debt relief; SGR replacement; NOTICE Act; Nurse staffing mandate; appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NOVARTIS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FRESENIUS MEDICAL CARE NORTH AMERICA (FKA FRESENIUS MEDICAL CARE) via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Medicare reimbursement; End stage renal disease (ESRD) payment reforms; extension of Medicare sequester; telehealth policy and waivers; issues pertaining to Medicare Secondary Payer Act; oral-only ESRD drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INDUCTIVEHEALTH INFORMATICS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to expanding support for modern disease and syndromic surveillance, immunization, and chronic disease infrastructure and technology.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASSOCIATION FOR RESPONSIBLE HEALTHCARE INVESTMENT via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy on federal policy proposals impacting private investment in healthcare. This includes legislative and regulatory initiatives related to clinical autonomy, workforce support, access to care in underserved communities, health system modernization, and transparency and accountability in healthcare delivery and investment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biopharmaceutical industry in Congress and throughout the Administration.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLAXOSMITHKLINE, INC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Strategic guidance and advocacy on health care related issues to include: healthcare reform, HIV/AIDS, bio-defense, Medicare/Medicaid and FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to physician payment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PREMIA SPINE via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to the Company's reimbursement and coding priorities.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
CURANA HEALTH, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to the Physician Fee Schedule
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
TEAMHEALTH via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to the Physician Fee Schedule
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
VITAE HEALTH SYSTEMS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to the Physician Fee Schedule.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
PHI HEALTH, LLC, D/B/A PHI AIR MEDICAL via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to ambulance legislative and regulatory issues.
Provide strategic counsel and advocate on issues related to ambulance legislative and regulatory issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
THE CHILDREN'S HOSPITAL OF PHILADELPHIA via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and The Children's Hospital of Philadelphia specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL ALLIANCE FOR CARE AT HOME via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to home health, home care and hospice policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
FEDERATION OF AMERICAN HOSPITALS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to health policy and hospitals
Provide strategic counsel and advocate on issues related to health policy and hospitals
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic guidance and advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
COLORECTAL CANCER ALLIANCE via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to colorectal cancer research and funding
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
REAL TIME MEDICAL SYSTEMS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel related to federal health care policy impacting nursing facilities and assisted living settings.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FINDHELP via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy on federal health policy related to social care programs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office
LUMEXA IMAGING, INC. (FKA US RADIOLOGY SPECIALISTS) via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provided strategic counsel on matters before HHS and the Congress, including surprise medical billing and Medicare payment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
RADIOLOGY PARTNERS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provided strategic counsel on matters before HHS and the Congress, including surprise medical billing and Medicare payment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
OAK STREET HEALTH D/B/A CVS HEALTH via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy on issues impacting value-based primary care centers for Medicare beneficiaries generally, and Oak Street Health specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · RR
Provide strategic counsel and advocate on issues related to physician payment.
THE CHILDREN'S HOSPITAL OF PHILADELPHIA via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and The Children's Hospital of Philadelphia specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic guidance and advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REAL TIME MEDICAL SYSTEMS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel related to federal health care policy impacting nursing facilities and assisted living settings.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FINDHELP via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy on federal health policy related to social care programs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office
LUMEXA IMAGING, INC. (FKA US RADIOLOGY SPECIALISTS) via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provided strategic counsel on matters before HHS and the Congress, including surprise medical billing and Medicare payment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
RADIOLOGY PARTNERS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provided strategic counsel on matters before HHS and the Congress, including surprise medical billing and Medicare payment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
OAK STREET HEALTH D/B/A CVS HEALTH via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy on issues impacting value-based primary care centers for Medicare beneficiaries generally, and Oak Street Healthspecifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PREMIA SPINE via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to the Company's reimbursement and coding priorities.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals and health plans generally and Mass General Brigham specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE
PTC THERAPEUTICS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and advocacy with regard to regulations and legislation that could impact the pharmaceutical industry generally, and PTC specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CURANA HEALTH, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to the Physician Fee Schedule
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
SCP-HEALTH via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic guidance and counsel on policy issues impacting emergency medicine and issues related to acute unscheduled care including physician fee schedule
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TEAMHEALTH via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to the Physician Fee Schedule
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
AKEBIA THERAPEUTICS, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic guidance and counsel on issues impacting the biopharmaceutical industry and legislation to provide greater access to kidney care.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VITAE HEALTH SYSTEMS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to the Physician Fee Schedule.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
PHI HEALTH, LLC, D/B/A PHI AIR MEDICAL via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to ambulance legislative and regulatory issues.
Provide strategic counsel and advocate on issues related to ambulance legislative and regulatory issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
U.S. ACUTE CARE SOLUTIONS, LLC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provided strategic counsel on matters before HHS and the Congress, including surprise medical billing and Medicare payment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN SOCIETY OF GENE AND CELL THERAPY via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic advice and counsel on issues impacting gene and cell therapy development and access
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WALGREEN CO. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide policy analysis, strategic advice and direct advocacy support to Walgreens related to public policy priorities for the retail pharmacy industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES LLC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL ALLIANCE FOR CARE AT HOME via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to home health, home care and hospice policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Advise and advocate on client's behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CENTENE CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic guidance and counsel related to Medicare, Medicaid, and the insurance market.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMEDISYS, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
GRADY HEALTH SYSTEM via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and policy advocacy related to federal payment and policy issues and government funding impacting hospitals generally and Grady Health System specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
VAXCYTE, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to vaccine development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEUROCRINE BIOSCIENCES, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FEDERATION OF AMERICAN HOSPITALS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to health policy and hospitals
Provide strategic counsel and advocate on issues related to health policy and hospitals
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
LOCKTON MANAGEMENT, LLC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic guidance and counsel on maintaining and strengthening the employer-based health care system, and advise the client on legislative and regulatory issues.
Filing targets: Commodity Futures Trading Commission (CFTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE, Securities & Exchange Commission (SEC), Transportation, Dept of (DOT), Treasury, Dept of
U.S. ANESTHESIA PARTNERS, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provided strategic counsel on matters before HHS and the Congress, including surprise medical billing and Medicare payment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NYU LANGONE HEALTH via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and NYU Langone Health specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
SENIOR CARE PHARMACY COALITION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031/ S.3159 Preserving Patient Access to Long-Term Care Pharmacies Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
COLORECTAL CANCER ALLIANCE via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to colorectal cancer research and funding
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ACADEMY OF NUTRITION AND DIETETICS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to health care coverage for Medical Nutritional Therapy and Intensive behavior health and other priorities for the Academy of Nutrition and Dietetics
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN HEALTH CARE ASSOCIATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Long-term care reform; Medicare and Medicaid payment policy; Medicare Advantage policy; arbitration issues; implementation of health care reform; bad debt relief; SGR replacement; NOTICE Act; Nurse staffing mandate; appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FRESENIUS MEDICAL CARE NORTH AMERICA (FKA FRESENIUS MEDICAL CARE) via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Medicare reimbursement; End stage renal disease (ESRD) payment reforms; extension of Medicare sequester; telehealth policy and waivers; issues pertaining to Medicare Secondary Payer Act; oral-only ESRD drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ADVOCATE HEALTH via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on health care policy, including matters impacting the hospital industry and federal appropriations
Provide strategic counsel and advocate on health care policy, including matters impacting the hospital industry and federal appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INDUCTIVEHEALTH INFORMATICS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to expanding support for modern disease and syndromic surveillance, immunization, and chronic disease infrastructure and technology.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASSOCIATION FOR RESPONSIBLE HEALTHCARE INVESTMENT via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy on federal policy proposals impacting private investment in healthcare. This includes legislative and regulatory initiatives related to clinical autonomy, workforce support, access to care in underserved communities, health system modernization, and transparency and accountability in healthcare delivery and investment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIFTKEY, LLC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to healthcare workforce and technology and independent contractor classification
Filing targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE, Veterans Affairs, Dept of (VA)
INTERSYSTEMS PUBLIC SECTOR CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to health care, veteran affairs and corresponding technology modernization
Provide strategic counsel and advocate on issues related to health care, veteran affairs and corresponding technology modernization
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA), White House Office
AMGEN INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biopharmaceutical industry in Congress and throughout the Administration.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLAXOSMITHKLINE, INC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic guidance and advocacy on health care related issues to include: healthcare reform, HIV/AIDS, bio-defense, Medicare/Medicaid and FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PREMIA SPINE via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · RR
Provide strategic counsel and advocate on issues related to the Company's reimbursement and coding priorities.
CURANA HEALTH, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · RR
Provide strategic counsel and advocate on issues related to the Physician Fee Schedule.
TEAMHEALTH via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · RR
Provide strategic counsel and advocate on issues related to the Physician Fee Schedule.
VITAE HEALTH SYSTEMS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · RR
Provide strategic counsel and advocate on issues related to the Physician Fee Schedule.
PHI HEALTH, LLC, D/B/A PHI AIR MEDICAL via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · RR
Provide strategic counsel and advocate on issues related to ambulance legislative and regulatory issues.
Provide strategic counsel and advocate on issues related to ambulance legislative and regulatory issues.
SCP-HEALTH via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · 1A
Provide strategic guidance and counsel on policy issues impacting emergency medicine and issues related to acute unscheduled care including physician fee schedule
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals and health plans generally and Mass General Brigham specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
OAK STREET HEALTH D/B/A CVS HEALTH via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocacy on issues impacting value-based primary care centers for Medicare beneficiaries generally, and Oak Street Healthspecifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE